Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial

Andriole, Gerald L.; Guess, Harry A.; Epstein, Jonathan I.; Wise, Henry; Kadmon, Dov; Crawford, E. David; Hudson, Perry B.; Jackson, Craig; Romas, Nicholas A.; Patterson, Lynn; Cook, Thomas J.; Waldstreicher, Joanne

doi:10.1016/s0090-4295(98)00184-8

Cited by 175 publications

(41 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An explanation could be that SRD5A2 promoter hypermethylation causes the absence of SRD5A2 expression, and an androgenic to estrogenic switch in prostate tissue. This hypothesis is supported by our recent studies and others [17,[33][34][35]. In BPH tissues, we showed that the level of estradiol is dramatically elevated in prostatic samples with methylation of the SRD5A2 promoter, a condition that favors an estrogenic, as opposed to an androgenic, milieu in the prostate.…”

Section: Srd5a2 Promoter Methylation Was Negatively Associated With Ssupporting

confidence: 87%

Methylation of SRD5A2 promoter predicts a better outcome for castration-resistant prostate cancer patients undergoing androgen deprivation therapy

et al. 2020

View full text Add to dashboard Cite

PurposeTo determine whether SRD5A2 promoter methylation is associated with cancer progression during androgen deprivation therapy (ADT) in CRPC.analysis showed that SRD5A2 methylation was associated with OS independently (whole promoter region: P = 0.035; specific region: P = 0.02). ConclusionOur study demonstrate that SRD5A2 methylation in promoter regions, specifically at CpG# -39 to -2, is significantly associated with better survival for CRPC patients treated with ADT. Recognition of epigenetic modifications of SRD5A2 may affect the choices and sequence of available therapies for management of CRPC. PLOS ONESRD5A2 methylation predicts a better outcome for CRPC PLOS ONE | https://doi.org/10.

show abstract

Section: Srd5a2 Promoter Methylation Was Negatively Associated With Ssupporting

confidence: 87%

Methylation of SRD5A2 promoter predicts a better outcome for castration-resistant prostate cancer patients undergoing androgen deprivation therapy

et al. 2020

View full text Add to dashboard Cite

show abstract

“…It tried to analyze the diagnostic rate for prostate cancer based on a PSA level of 4 mg/ml. According to this study, there was a similar profile of sensitivity (66% vs. 70%) and specificity (82% vs. 74%) as compared with the placebo-controlled group when the actual PSA level was applied [26]. Regarding dutasteride, Andriole et al reported that the PSA level was increased by 8.3% in year 2 in the placebo-controlled group [27].…”

Section: Discussionmentioning

confidence: 83%

The Different Reduction Rate of Prostate-Specific Antigen in Dutasteride and Finasteride

Choi

Cho

2010

Korean J Urol

View full text Add to dashboard Cite

PurposeTo compare and analyze the therapeutic effects and changes in the prostate-specific antigen (PSA) level with treatment with finasteride or dutasteride for benign prostatic hyperplasia (BPH) for 1 year.Materials and MethodsWe retrospectively investigated patients who suffered from BPH for 1 year between January 2005 and December 2008. For treatment groups, we divided the patients into two groups: one was treated with alfuzosin and finasteride and the other was treated with alfuzosin and dutasteride. At the beginning of treatment, the patients underwent transrectal ultrasonography and measurement of urine flow rate, residual urine volume, PSA, and International Prostate Symptom Score (IPSS). Patients with diseases affecting urinary function were excluded. We not only analyzed the data at the time of initial treatment, but also after 1 year of treatment. A total of 219 patients were able to be evaluated for 1 year.ResultsBoth finasteride and dutasteride reduced PSA and prostate volume significantly. The comparison between groups showed a more significant reduction of PSA (p=0.020) and prostate volume (p=0.052) in the dutasteride group. Other parameters did not differ significantly between the groups.Conclusions5-α Reductase inhibitors for BPH treatment reduced PSA and prostate volume significantly when the patients were treated for 1 year. Administration of dutasteride is considered to be more effective in reducing PSA and prostate volume. Therefore, dutasteride should not be considered equivalent to finasteride in the reduction rate of PSA. The intensity of dutasteride must be reevaluated in comparison with finasteride.

show abstract

“…No additional patient benefits have been seen when finasteride is combined with α 1 –blockers [29, 30]. Although finasteride lowers serum PSA levels, it does not mask the early detection of prostate cancer [31, 32]. …”

Section: Treatment Of Bphmentioning

confidence: 99%

EAU Guidelines on Benign Prostatic Hyperplasia (BPH)

et al. 2001

View full text Add to dashboard Cite

Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial

Cited by 175 publications

References 21 publications

Methylation of SRD5A2 promoter predicts a better outcome for castration-resistant prostate cancer patients undergoing androgen deprivation therapy

Methylation of SRD5A2 promoter predicts a better outcome for castration-resistant prostate cancer patients undergoing androgen deprivation therapy

The Different Reduction Rate of Prostate-Specific Antigen in Dutasteride and Finasteride

EAU Guidelines on Benign Prostatic Hyperplasia (BPH)

Contact Info

Product

Resources

About